Cetuximab strongly enhances immune cell infiltration into liver metastatic sites in colorectal cancer
暂无分享,去创建一个
H. Nagano | Ryouichi Tsunedomi | S. Hazama | Michihisa Iida | Y. Tokuhisa | K. Sakamoto | N. Suzuki | S. Yoshino | S. Kanekiyo | T. Ueno | Y. Inoue | Shinobu Tomochika | S. Takeda | Y. Tokumitsu | Kazuhiko Sakamoto | Yukio Tokumitsu
[1] J. Sakamoto,et al. A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study). , 2016, Clinical colorectal cancer.
[2] A. Bardelli,et al. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death , 2016, Nature Medicine.
[3] J. Galon,et al. Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. , 2016, International immunology.
[4] Yusuke Nakamura,et al. Characterization of the T cell repertoire by deep T cell receptor sequencing in tissues and blood from patients with advanced colorectal cancer , 2016, Oncology letters.
[5] J. Sakamoto,et al. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study , 2015, BMC Cancer.
[6] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[7] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[8] L. Terracciano,et al. NK cells and T cells cooperate during the clinical course of colorectal cancer , 2014, Oncoimmunology.
[9] M. Oka,et al. FcγR and EGFR Polymorphisms as Predictive Markers of Cetuximab Efficacy in Metastatic Colorectal Cancer , 2014, Molecular Diagnosis & Therapy.
[10] Yusuke Nakamura,et al. A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study) , 2014, Journal of Translational Medicine.
[11] J. Sakamoto,et al. Multicenter phase II study of second-line cetuximab plus folinic acid/5-fluorouracil/irinotecan (FOLFIRI) in KRAS wild-type metastatic colorectal cancer: the FLIER study. , 2014, Anticancer research.
[12] Yusuke Nakamura,et al. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome , 2014, Journal of Translational Medicine.
[13] Jianming Xu,et al. Effect of Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases , 2014, PloS one.
[14] M. Oka,et al. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI‐treated metastatic colorectal cancer in two prospective studies in Japan , 2013, Cancer science.
[15] M. Oka,et al. UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer. , 2013, Anticancer research.
[16] D. McMillan,et al. The in situ local immune response, tumour senescence and proliferation in colorectal cancer , 2013, British Journal of Cancer.
[17] F. Marincola,et al. Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.
[18] D. McMillan,et al. The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. , 2012, Cancer treatment reviews.
[19] H. Sorbye,et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. McMillan,et al. The relationships between cellular components of the peritumoural inflammatory response, clinicopathological characteristics and survival in patients with primary operable colorectal cancer , 2012, British Journal of Cancer.
[21] K. Muro,et al. Cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer: results from the randomised phase II part of a phase I/II study. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] D. McMillan,et al. Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer , 2012, The British journal of surgery.
[23] Axel Benner,et al. Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. , 2011, Cancer research.
[24] D. Lambrechts,et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial , 2011, The Lancet.
[25] J. Sakamoto,et al. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms. , 2011, Japanese journal of clinical oncology.
[26] C. Mathers,et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.
[27] Josep Tabernero,et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] I. Hyodo,et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). , 2010, The Lancet. Oncology.
[29] I. Salmon,et al. Putative contribution of CD56 positive cells in cetuximab treatment efficacy in first-line metastatic colorectal cancer patients , 2010, BMC Cancer.
[30] D. McMillan,et al. Comparison of the Prognostic Value of Inflammation-Based Pathologic and Biochemical Criteria in Patients Undergoing Potentially Curative Resection for Colorectal Cancer , 2009, Annals of surgery.
[31] Hayao Nakanishi,et al. Interleukin‐2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor‐overexpressing gastric cancer xenografts through antibody‐dependent cellular cytotoxicity , 2008, Cancer science.
[32] W. Scheithauer,et al. Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] G. Weiner. Monoclonal antibody mechanisms of action in cancer , 2007, Immunologic research.
[34] M. Nakamoto,et al. Antibody-Dependent Cellular Cytotoxicity Mediated by Cetuximab against Lung Cancer Cell Lines , 2007, Clinical Cancer Research.
[35] Z. Trajanoski,et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.
[36] J. Melkko,et al. Inflammation and prognosis in colorectal cancer. , 2005, European journal of cancer.
[37] B. Burtness,et al. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. , 2005, Drugs of today.
[38] I. Hyodo,et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] C. Tournigand,et al. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] S. Takeno,et al. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. , 2003, Oncology reports.
[41] E Harrison,et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] C. Wilson,et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] H Nagura,et al. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. , 1998, Cancer research.
[44] J. Sakamoto,et al. Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study. , 2014, Anticancer research.
[45] M. Kloor,et al. The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. , 2009, Cancer immunity.
[46] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.